How to Cash In on 2025’s M&A Explosion
From tech to energy, 2025’s dealmaking surge offers multiple profit opportunities. See how to profit from historic M&A activity.
This Biotech Has a Tech Company’s DNA
Most biotechs burn cash, but this one’s turning heads with its 34.8x return on invested capital and PE ratio of 18.6x – well below industry average.
Can Analysts Predict Stock Moves Before They Happen?
From Uber’s recent surge to the science behind ratings, here’s what you need to know about market forecasts.
Market Check: Why I’m Not Worried (Yet)
Markets remain inches from record highs despite recent weakness. While the Magnificent Seven show concerning divergence, we haven’t seen a 5% correction since fall.
Dealmaker’s Diary: A Double Dose of Tickers
By reader request, Alpesh rates a cutting-edge biotech with 232% potential upside and a semiconductor giant with low volatility.
Dealmaker’s Diary: Data Over Drama Gives This Stock 50% Upside
While headlines focus on insurance sector challenges, one company’s fundamentals suggest a very different narrative ahead.
Dealmaker’s Diary: The Contrarian Play That Defies Market Logic
Despite industry headwinds and natural disasters, this $4.6 billion insurance company shows surprising strength. Our proprietary GVI analysis reveals why market fear creates your opportunity.
The Hidden Winners of the Los Angeles Recovery
As the smoke clears from California’s worst disaster, billions in rebuilding funds are about to flow. Here are the companies best positioned to capture this massive opportunity…
Monday Takeaways: A Strong Jobs Report Rattles Markets
A surprisingly strong jobs report and rising bond yields are creating market turbulence. Here’s what it means for your money…
Dealmaker’s Diary: An Energy Giant With 34.7% Upside
This energy stalwart, backed by Berkshire Hathaway’s 28% stake, is in perfect position for an energy boom.